Business of Biotech is a workshop series that introduces grad students, postdocs and faculty from Yale and UConn to the core skills and building blocks to translate their research to the marketplace. This lecture and workshop series is designed to provide researchers in the life sciences with a comprehensive introduction to the bioscience business environment by exploring the process of transforming a scientific idea into a value-generating product.
Presented by the Office of Cooperative Research and Yale Entrepreneurial Institute with support from the Yale Healthcare and Lifesciences Club, Canaan Partners, Wilson Sonsini Goodrich & Rosati, Jackson Labs and Alexion Pharmaceuticals.
MON., SEPT. 19, 5:30-7:30pm: “Elements of a Business Plan and Sources of Capital for Early Stage Life Science Companies” with Colleen Cuffaro, Associate at Canaan Partners. Guest speakers for case studies include: Jason Hafler, Senior Director of Investments and Principal at Sanofi-Genzyme BioVentures; Susan Froshauer, President & CEO of Connecticut United for Research Excellence; Arthur Hiller, CEO of ENB Therapeutics and CEO of Antyllus Therapeutics, Inc; Lou Degennaro, President of Leukemia & Lymphoma Society.
TUES., SEPT. 20, 5:30-7:30pm: “Intellectual Property and Regulatory Considerations for Early Stage Life Science Companies” with Craig Kenesky, Associate Patent Attorney at WSGR. Guest speakers for case studies include: Erika Smith, Director of the Blavatnik Fund for Innovation at Yale; Cameron Pitt, Investment Professional at Versant Ventures and Associate at Highline Therapeutics; Angela Shen, CMO of Arvinas Inc.
WED., SEPT. 21, 5:30-7:30pm: “Marketing and Operations Considerations for Early Stage Life Science Companies” with Andrey Antov, Program Director of the Maine Cancer Genomics Initiative at The Jackson Laboratory. Guest speakers for case studies include: Daniel Wagner, Managing Director of Investments of Connecticut Innovations; Daniel Passeri, CEO of Context Pharma.
October 19, 5:30-7:30pm: “Case Studies in Life Science Entrepreneurship” with Manon Cox, President & CEO, Protein Sciences Corporation; Arikha Moses, Founder & Senior Executive, Galatea Surgical and Milind Deshpande, President & CEO, Achillion Pharmaceuticals
November 16, 5:30-7:30pm: “Tech Transfer - IP & Licensing” with Leslie-Anne Maxwell, Partner and Pharmaceutical Patent Services Group Leader, Cantor Colburn, Erika Smith, Director of the Blavatnik Fund for Innovation at Yale and David Lewin, Senior Associate Director of Licensing at the Yale Office of Cooperative Research.
December 12, 5:30-7:30pm (Please note Monday!): Science of Schmoozing -Learning the Keys to Networking with Scott Nevins, Principal at Bernstein Global Wealth Management and Jim Boyle, Managing Director of the Yale Entrepreneurial Institute. Get ready for the season of networking with expert advice and fun hands-on activities to successfully prepare you to build relationships at your next networking event. Try out your skills at the CURE Holiday Party the following evening!
December 13, 5-7pm: CURE Holiday Party (at Alexion, 100 College St.) Register here.
January 25, 5:30-7:30pm: “Trends in Life Science Funding & Exits, Corporate Strategy & Business Development” with Marcia Dougan-Moore, Vice President, Development Operations at Arvinas and Tim Shannon, General Partner, Canaan Partners.
February 15, 5:30-7:30pm: “From Lab to Clinical Trials” with Sean Cassidy, CFO, Arvinas. This session will cover Equity Financing (Seed Rounds, Preferred Stock Financings, Mezzanines Financings) and the Basics of Financial Reporting and Budgeting (Balance Sheet, Income Statement, Cash Flow Statement, Corporate Goals and budgeting process).
March 1, 5:30-7:30pm: “Bridging the Valley of Death: New Models for Developing Breakthrough Discoveries into Medicines” with Baiju Shah, CEO, Biomotiv (at YEI, 254 Elm St., 3rd Floor). *Co-sponsored by the Yale Entrepreneurial Society.
March 9, 5:30-7:30pm: “Drug Discovery A to Z: Go Ahead And Ask.” Join veteran drug discovery scientists from Charles River for a frank discussion about the drug discovery process.
5:30 pm - 6:15 pm: How Do We Prove a Drug Action is Selective? John Montana, PhD
This talk will describe oversight of the drug discovery process within the pharma & biotech environment and focus on the importance of target engagement biomarkers and the role they can play from a translational efficacy and side effect liability perspective
6:15 pm: All You Need to Know About Drug Development but Were Afraid to Ask (Q&A Round Table)
Questions from the audience will drive a round table featuring a team of experienced drug discovery scientists from Charles River. This interactive session will touch on topics of interest from the audience regarding any aspect of drug discovery, from basic science through the out-licensing of projects and technologies.
April 19, 5:30-7:30pm: Pitch Preparation with Canaan Partners (at Alexion, 100 College St., New Haven). Colleen Cuffaro - Principal at Canaan Partners - will lead a talk on best practices when pitching to biotech and tech investors. All applicants to the Poster Session/Pitch Contests for the Yale Innovation Summit are highly encouraged to attend.
May 10, 8am-5pm: Yale Innovation Summit (at School of Management, 165 Whitney Ave., New Haven). The Yale Innovation Summit is a day-long event tailored to Yale innovators to encourage the sharing of new discoveries and technologies with market potential with the broader investment community. Two tracks–biotech and tech, panels and keynotes from leading biotech and tech investors, an electronic poster session featuring cutting-edge Yale technologies, breakfast, lunch, networking opportunities and more. New this year: Blavatnik Fund for Innovation at Yale awards ceremony and closing remarks by Yale President Peter Salovey. Cofirmed VC Firms: 5AM Ventures, Atlas Venture, F-Prime Capital Partners, TPG Capital, Nyca Partners, OrbiMed, Polaris Partners, New Enterprise Associates, Oak HC/FT, New Leaf Venture Partners, Samsung Ventures, Polaris Partners, Sanofi-Genzyme BioVentures, Johnson & Johnson, Novartis Venture Funds, Evolution Life Science Partners. DETAILS AND REGISTRATION.